Wealth Enhancement Advisory Services LLC Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Wealth Enhancement Advisory Services LLC grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 66.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,381 shares of the biotechnology company’s stock after buying an additional 29,797 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in BioMarin Pharmaceutical were worth $4,277,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Farther Finance Advisors LLC boosted its stake in BioMarin Pharmaceutical by 95.9% during the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 211 shares during the last quarter. Rise Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical in the 1st quarter valued at about $30,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of BioMarin Pharmaceutical by 71.2% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 218 shares during the last quarter. Brooklyn Investment Group grew its stake in BioMarin Pharmaceutical by 2,250.0% in the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 540 shares in the last quarter. Finally, Banque Transatlantique SA bought a new stake in BioMarin Pharmaceutical in the first quarter valued at about $71,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $52.62 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. The firm has a market capitalization of $10.10 billion, a PE ratio of 15.61, a P/E/G ratio of 0.69 and a beta of 0.35. BioMarin Pharmaceutical Inc. has a 1-year low of $52.47 and a 1-year high of $73.51. The business’s fifty day moving average price is $57.24 and its two-hundred day moving average price is $59.45.

Wall Street Analyst Weigh In

BMRN has been the topic of a number of research analyst reports. Wall Street Zen raised BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 13th. UBS Group upped their price target on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Guggenheim lifted their price objective on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. HC Wainwright initiated coverage on shares of BioMarin Pharmaceutical in a research note on Monday, September 8th. They set a “neutral” rating and a $60.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $92.60.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.